John Sarantopoulos

5.4k citations
82 papers · 4k · 3 hit papers · h-index 31

Impact in

Papers in

    • Cancer Treatment and Pharmacology 10
    • Colorectal Cancer Treatments and Studies 8
    • Cancer Immunotherapy and Biomarkers 6
    • Pharmacogenetics and Drug Metabolism 16

John Sarantopoulos

80 papers receiving 3.9k citations

John Sarantopoulos's Hit Papers

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial 2022 · 212 citations
2120+2+4Years since publication100200300

Peers

John Sarantopoulos
Comparison fields: 5 of 86
  • Oncology 1.1k
  • Drug Discovery 6
  • Biomaterials 248
  • Pulmonary and Respiratory Medicine 556
  • Genetics 147
Replace Nehal J. Lakhani with:
Nehal J. Lakhani United States
Dominik Rüttinger Germany
Alison L. Hannah United States
Giulio Francia United States
David R. Shalinsky United States
Muralidhar Beeram United States
Mansoor M. Ahmed United States
Michael W. Becker United States
Lisa A. Hammond United States
Elin Hegland Kure Norway
John Sarantopoulos relative to Nehal J. Lakhani United States Nehal J. Lakhani's profile →
Citations per field
00.5×2×4×6×7.3×
Nehal J. Lakhani · 1×
Citations per year

Countries citing papers authored by John Sarantopoulos

Since Specialization
Citations

This map shows the geographic impact of John Sarantopoulos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Sarantopoulos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Sarantopoulos more than expected).

Fields of papers citing papers by John Sarantopoulos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Sarantopoulos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Sarantopoulos. The network helps show where John Sarantopoulos may publish in the future.

Co-authors

The 25 scholars most cited alongside John Sarantopoulos, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John Sarantopoulos Line = papers co-authored together John Sarantopoulos links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 82 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
Hit paper breakdown →
2020367
2
Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
Hit paper breakdown →
2021299
3 2009264
4 2014263
5
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Hit paper breakdown →
2022212
6 2014201
7 2013164
8 2011155
9 2015154
10 2022141
11 201094
12 201090
13 201778
14 201977
15 201276
16 201671
17 201265
18 202061
19 201357
20 201953

About John Sarantopoulos

John Sarantopoulos is a scholar working on Oncology, Pharmacology, Molecular Biology, Pulmonary and Respiratory Medicine and Statistics and Probability, having authored 82 papers that have together received 4k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (16 papers), Cancer Treatment and Pharmacology (10 papers), Colorectal Cancer Treatments and Studies (8 papers), Angiogenesis and VEGF in Cancer (7 papers), Lung Cancer Treatments and Mutations (6 papers), Cancer Immunotherapy and Biomarkers (6 papers), PI3K/AKT/mTOR signaling in cancer (6 papers) and Statistical Methods in Clinical Trials (5 papers). The work is most often cited by research in Oncology (1.1k citations), Drug Discovery (6 citations), Biomaterials (248 citations), Pulmonary and Respiratory Medicine (556 citations) and Genetics (147 citations). John Sarantopoulos has collaborated with scholars based in United States, Switzerland and Spain. Frequent co-authors include Devalingam Mahalingam, Alain C. Mita, Monica M Mita, Anthony W. Tolcher, Tyler Jay Curiel, Francis Joseph Giles, Chia‐Chi Lin, Jordi A. Rodon, Kamalesh Kumar Sankhala and Leslie Wood. Their work appears in journals such as Cancer Chemotherapy and Pharmacology, Clinical Cancer Research, Investigational New Drugs, Annals of Oncology and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact